Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D. Smith(Deciphera Pharmaceuticals (United States)), Michael D. Kaufman(Deciphera Pharmaceuticals (United States)), Wei-Ping Lu(Deciphera Pharmaceuticals (United States)), Anu Gupta(Deciphera Pharmaceuticals (United States)), Cynthia B. Leary(Deciphera Pharmaceuticals (United States)), Scott Wise(Deciphera Pharmaceuticals (United States)), Thomas J. Rutkoski(Deciphera Pharmaceuticals (United States)), Yu Mi Ahn(Deciphera Pharmaceuticals (United States)), Gada Al-Ani(Deciphera Pharmaceuticals (United States)), Stacie L. Bulfer(Deciphera Pharmaceuticals (United States)), Timothy M. Caldwell(Deciphera Pharmaceuticals (United States)), Lawrence Chun, Carol L. Ensinger(Deciphera Pharmaceuticals (United States)), Molly M. Hood(Deciphera Pharmaceuticals (United States)), Arin McKinley(Portland VA Medical Center), William C. Patt(Deciphera Pharmaceuticals (United States)), Rodrigo Ruiz‐Soto(Deciphera Pharmaceuticals (United States)), Ying Su(Deciphera Pharmaceuticals (United States)), Hanumaiah Telikepalli(Deciphera Pharmaceuticals (United States)), Ajia Town(Portland VA Medical Center), Benjamin A. Turner(Deciphera Pharmaceuticals (United States)), Lakshminarayana Vogeti(Deciphera Pharmaceuticals (United States)), Subha Vogeti(Deciphera Pharmaceuticals (United States)), Karen Yates(Deciphera Pharmaceuticals (United States)), Filip Jankú(The University of Texas MD Anderson Cancer Center), Albiruni Ryan Abdul Razak(Princess Margaret Cancer Centre), Oliver Rosen(Deciphera Pharmaceuticals (United States)), Michael C. Heinrich(Portland VA Medical Center), Daniel L. Flynn(Deciphera Pharmaceuticals (United States))
Cited by 276
Abstract
Related Papers
No related papers found
Powered by citation graph analysis